Hematology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Myelodysplastic Syndrome Therapy
New findings from University of Michigan in the area of myelodysplastic syndrome therapy described
April 16th, 2007
Research findings, "Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer," are discussed in a new report. "Anemia is common in patients with cancer or myelodysplastic syndrome. Erythropoietic therapy offers an effective way to manage anemia by increasing hemoglobin levels, decreasing transfusion requirements, and alleviating symptoms," researchers in the United States report. "We reviewed data showing the feasibility and effectiveness of treatment with the erythropoiesis-stimulating protein darbepoetin alfa at extended dosing intervals to treat anemia in patients with cancer receiving multicycle chemotherapy. We...
Source: Hematology Week (2007-04-16)
|
